Ani Pharmaceuticals (ANIP) Return on Capital Employed (2012 - 2026)
Ani Pharmaceuticals (ANIP) reported Return on Capital Employed of 10.39% for Q1 2026, up 979.0% on a YoY basis from 0.96% in Q1 2025, and up 7.17% sequentially from 9.69% in Q4 2025.
Ani Pharmaceuticals (ANIP) Return on Capital Employed (2012 - 2026) Analysis & Trends
Ani Pharmaceuticals (ANIP) has 15 years of Return on Capital Employed data on file, last reported at 10.39% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 979.0% year-over-year to 10.39%; the trailing twelve-month figure through Mar 2026 stood at 10.39% (up 979.0% YoY), and the FY2025 full-year result was 10.25%, up 1018.0% from the prior year.
- Return on Capital Employed improved to 10.39% in Q1 2026, from 9.69% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 10.39% in Q1 2026 to a low of 9.17% in Q3 2022.
- A 5-year average of 1.45% and a median of 1.41% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 779 bps in 2022 and jumped 1485 bps in 2023, its largest moves.
- Tracing ANIP's Return on Capital Employed over 5 years: stood at 5.43% in 2022, then jumped by 215 bps to 6.25% in 2023, then plunged by 99 bps to 0.05% in 2024, then surged by 18015 bps to 9.69% in 2025, then climbed by 7 bps to 10.39% in 2026.
- Business Quant data shows ANIP's Return on Capital Employed at 10.39% in Q1 2026, 9.69% in Q4 2025, and 6.51% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 10.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.39% |
| Dec 31, 2025 | 9.69% |
| Sep 30, 2025 | 6.51% |
| Jun 30, 2025 | 1.41% |
| Mar 31, 2025 | 0.60% |
| Dec 31, 2024 | 0.05% |
| Sep 30, 2024 | 1.28% |
| Jun 30, 2024 | 6.45% |
| Mar 31, 2024 | 7.43% |
| Dec 31, 2023 | 6.25% |
| Sep 30, 2023 | 5.68% |
| Jun 30, 2023 | 2.77% |
| Mar 31, 2023 | -0.97% |
| Dec 31, 2022 | -5.43% |
| Sep 30, 2022 | -9.17% |
| Jun 30, 2022 | -9.11% |
| Mar 31, 2022 | -9.14% |
| Dec 31, 2021 | -7.46% |
| Sep 30, 2021 | -4.03% |
| Jun 30, 2021 | -2.45% |